Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03389347 · OUTCOME

Number of Participants With Actionable Assay Response

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia · Source last updated 2026-05-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 21 days

What was measured

The feasibility of this approach will be assessed in terms of obtaining an actionable response from the proposed assay in at least 50% of patients examined.

Analysis population: Of the 40 patients enrolled, 35 obtained actionable response from the assay within 21 days.

Groups in this outcome

Device Feasibility (High-throughput Assay, Sequencing)

Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians. Biospecimen Collection: Undergo collection of bone marrow aspirate and blood High Throughput Screening: Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay Laboratory Biomarker Analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Device Feasibility (High-throughput Assay, Sequencing)40

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Device Feasibility (High-throughput Assay, Sequencing)35Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        35
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    units
    Participants
description
The feasibility of this approach will be assessed in terms of obtaining an actionable response from the proposed assay in at least 50% of patients examined.
groups
  1. description
    Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians. Biospecimen Collection: Undergo collection of bone marrow aspirate and blood High Throughput Screening: Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay Laboratory Biomarker Analysis: Correlative studies
    id
    OG000
    title
    Device Feasibility (High-throughput Assay, Sequencing)
param Type
COUNT_OF_PARTICIPANTS
population Description
Of the 40 patients enrolled, 35 obtained actionable response from the assay within 21 days.
reporting Status
POSTED
time Frame
Up to 21 days
title
Number of Participants With Actionable Assay Response
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice